Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Client Area Book a 7-day Readout
AmyPore logo — New target, new paradigm, new strategy that address the root...

AmyPore

New target, new paradigm, new strategy that address the root cause of Alzheimer, Parkinson, and other proteinopathies

Founded 2018 France France 2 employees Non Equity Assistance Total: $71.43K Biotechnology, Health Care +1

General Information

Company Name AmyPore
Founded Year 2018
Location France France
Employees 2
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Non Equity Assistance
Social

BounceWatch is an independent company data service, not affiliated with AmyPore. To contact AmyPore, visit amypore.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AmyPore compare?

A PDF of AmyPore and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AmyPore soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AmyPore

AmyPore is a biotechnology company with a focus on tackling neurodegenerative diseases such as Alzheimer and Parkinson. Founded in 2018 and based in France, the company is built around the groundbreaking work of Pr. Nouara Yahi and Pr. Jacques Fantini from the University of Aix-Marseille and Institut Universitaire de France. Their expertise in molecular neurosciences has led to the development of AmyP53, a patented non-toxic molecule designed to address a common mechanism of neurotoxicity in these debilitating diseases. The company's approach involves the use of a pioneering computational discovery platform and advanced binding technologies to identify and neutralize novel targets associated with pathologic protein misfolding. AmyPore also holds exclusive patent rights for the therapeutic use of AmyP53, including the development of a nasal spray for the treatment of Alzheimer's and Parkinson's diseases. Additionally, the company is working on a pipeline of therapeutic peptides aimed at preventing the formation of oligomers implicated in the development and progression of degenerative proteinopathies, such as amyotrophic lateral sclerosis (ALS) and type 2 diabetes. In April 2019, AmyPore secured Non-Equity Assistance investment from Incubateur Impulse, further validating the potential of their innovative approach. With its pioneering science and promising therapeutic developments, AmyPore has the potential to significantly impact the field of neurodegenerative disease treatment.

Business keywords: neurosciences, drug development, therapeutic peptides, molecular dynamics simulations, neurodegenerative diseases, proteinopathies, Alzheimer's disease, Parkinson's disease, drug design, calcium imaging, lipid-protein interactions, neurotoxicity, oligomers

Services & Products

Development of therapeutic peptides for treating neurodegenerative diseases such as Alzheimer's and Parkinson's

Target Customers

Patients suffering from neurodegenerative diseases healthcare providers biotechnology and pharmaceutical companies research institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance Undisclosed 1
Incubateur Impulse
Incubateur Impulse
03 Apr 2019
Grant €71.43K 1
EASME - EU Executive Agency for SMEs
01 Jan 2019

AmyPore Alternatives & Competitors

View All Alternatives
AmyPore vs
Wren Therapeutics
Wren Therapeutics United Kingdom

Stopping the wave of neurodegeneration at its source

Venture round
34 employees
Biopharma, Biotechnology
AmyPore vs
Accera
Accera

Pioneering breakthroughs in neurodegenerative therapies for Alzheimer’s, Parkinson’s, and age-relate...

Venture round
11-50 employees
Biotechnology, Health Care
AmyPore vs
Proclara Biosciences
Proclara Biosciences

Pioneering therapies to combat neurodegenerative diseases with innovative protein disaggregation tec...

Venture round
Biotechnology, Health Care
View all alternatives

FAQ About AmyPore

New target, new paradigm, new strategy that address the root cause of Alzheimer, Parkinson, and other proteinopathies
AmyPore was founded in 2018.
AmyPore is headquartered in France.
AmyPore operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on neurosciences, drug development, therapeutic peptides and molecular dynamics simulations. Its customers include Patients suffering from neurodegenerative diseases, healthcare providers and biotechnology and pharmaceutical companies.
AmyPore has approximately 2 employees.
AmyPore has completed 2 funding rounds, raising a total of $71.43K. The latest funding stage is Non Equity Assistance.
AmyPore offers: Development of therapeutic peptides for treating neurodegenerative diseases such as Alzheimer's and Parkinson's.
Top alternatives and competitors to AmyPore include Wren Therapeutics, Accera, Proclara Biosciences, Pangolin Therapeutics, Inc., APRINOIA Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AmyPore and Wren Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AmyPore, https://bouncewatch.com/company/amypore, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout